<DOC>
	<DOCNO>NCT01677013</DOCNO>
	<brief_summary>The study aim evaluate safety efficiency autologous bone marrow mononuclear cell transplantation treat selective patient type 2 Diabetes Mellitus . We hypothesize autologous bone marrow stem cell transplantation would promote β-cells regeneration directly differentiate transplant BMMCs stimulate local stem cell regeneration thus decrease eliminate need exogenous insulin improve β-cells function .</brief_summary>
	<brief_title>Autologous Bone Marrow Mononuclear Cell Transplantation Treating Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>To study safety efficacy bone marrow mononuclear cell transplantation type 2 diabetic . According intervention baseline characteristic , patient divide 4 arm .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes mellitus age 3070 stable dos medication least 3 month BMI &lt; 35 &gt; 18.5 secondary cause hyperglycemia pregnancy nurse positive autoimmune antibody diabetes severe complication concurrent disease active infection febrile illness allergy iodine history sign aortic aneurysm history active pancreatic disease know substance abuse alcoholism heavy smoking suitable condition upon investigator ' expertise</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 ; diabetes mellitus ; stem cell ; safety ; efficacy</keyword>
</DOC>